ACOART Intracranial ISR Pilot:Intracranial DCB in the Treatment of Intracranial In-stent Restenosis

Exclusion Criteria

• •Patients with stroke within 2 weeks before procedure;
• •any history of brain parenchyma or other intracranial subarachnoid, subdural or extradural hemorrhage in the past 30 days.
• •Those who have received thrombolysis within 24 hours before procedure;
• •Deterioration of neurological function within 24 hours before procedure (defined as NIHSS score increased by ≥ 4 points over the baseline)
• •patients with thrombus in target vessels.
• •in addition to ISR lesions, there are other primary intracranial lesions that need endovascular treatment.
• •Major surgery (including open femoral, aortic or carotid artery surgery) is planned within the past 30 days or within 90 days.
• •patients with renal artery, iliac artery and cardiac coronary artery requiring simultaneous intervention.
• •Combined with intracranial tumors, aneurysms or intracranial arteriovenous malformations.
• •Cardiac stroke or potential cardiogenic thromboembolism, with any of the following cardiogenic embolism causes: chronic or paroxysmal atrial fibrillation, mitral valve stenosis, mechanical valves, endocarditis, intracardiac thrombus or implant, dilated cardiomyopathy, spontaneous acoustic imaging of the left atrium;
• •patients with myocardial infarction within 6 weeks before procedure.
• •those who cannot tolerate general anesthesia due to insufficiency of heart, lung and other important organs.
• •patients with known severe hepatic and renal dysfunction.
• •patients with hemoglobin \< 100g / L, platelet count \< 100,000 / mm3, INR \> 1.5or with uncorrectable factors leading to bleeding.
• •patients who cannot receive dual antiplatelet therapy due to existing diseases or who are tested to be tolerant to dual antiplatelet therapy.
• •Patients with known severe allergies or contraindications to heparin, paclitaxel, contrast agents and other related intravascular treatment drugs
• •current alcohol or drug abuse, uncontrolled severe hypertension (systolic blood pressure \> 180mmHg or diastolic blood pressure \> 110mmHg).
• •Life expectancy \< 1 year.
• •pregnant or lactating women.
• •patients who are unable to complete follow-up due to cognitive, emotional disorders or mental illness.
• •Patients who are participating in other drug/device clinical trials and have not completed all follow-ups required by the programme;
• •According to the judgement of the investigator, other situations that are not suitable for enrollment